Abstract
The incidence of canine mammary carcinoma varies with age, breed, and spay status, being among the main tumors appearing in intact female dogs. Thirty-six canine mammary carcinoma patients received injections of canine interferon-β (cIFN-β) and HSV-thymidine kinase/ganciclovir (HSV-tk/GCV) carrying lipoplexes, into the tumor bed, immediately after surgery. Next, they started periodic subcutaneous injections of lipoplexes carrying a human granulocyte-macrophage colony stimulating factor and interleukin-2 mixed with allogeneic mammary carcinoma extracts. This combined strategy was safe and well tolerated. In addition, only two out of 26 patients treated with complete surgery developed a local relapse, and 0 out of 29 stage II and III patients displayed distant metastases, suggesting both local and systemic antitumor activities. The most encouraging result was the long survival times: 22 > 1 year (where 13 > 2 and 4 > 3 years), while maintaining a good quality of life. The preliminary results in five patients presenting with local disease, an additional HSV-tk/GCV plus cIFN-β gene treatment induced local antitumor activity, evidenced by four objective responses (one complete, three partial) and one stable disease. This successful outcome supports further studies to validate this approach not only for canine veterinary patients, but also for translation to human patients.
Highlights
Canine mammary carcinomas (CMCs) are among the most prevalent tumors in intact female dogs [1]
Results and Discussion detailed description of the treatment scheme appears in the Materials and Methods section, Vet.ASci
Based on our previous experience with canine melanoma [14], we proposed a similar scheme of this immunogene therapy approach for a new study in canine mammary carcinoma
Summary
Canine mammary carcinomas (CMCs) are among the most prevalent tumors in intact female dogs [1]. Because of the similarities with human breast carcinoma, CMCs have been proposed as models for studying human carcinogenesis [3] and prognostic factors [4,5]. CMCs have less treatment alternatives in comparison with human breast cancer; many new therapies used for human patients were not validated for companion animals, and most of them would be too expensive and prohibitive for owners. In the veterinary oncology context, the development of new simple and affordable approaches is compelling. Along this way, cancer immunogene therapy is an especially suitable and fast expanding field that was reasonably
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
